Company intelligence / Profile preview

Suicide Zero

Huddinge, Sweden

Ownership: Private
Development stage: Other

Overview

SuicideZero was a Swedish biotechnology company that specialized in the development of targeted gene therapies for the treatment of various cancers. The company utilized a 'suicide gene' approach, primarily focusing on the Herpes Simplex Virus Thymidine Kinase (HSV-TK) system in conjunction with ganciclovir to induce selective cell death in malignant tissues. Originating from research at the Karolinska Institutet, the firm sought to create highly specific delivery mechanisms to reduce systemic toxicity. SuicideZero was liquidated in 2018 and is no longer active in drug development.

Therapeutic areas: Oncology
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Suicide Zero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suicide Zero.

Explore the full profile